OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Arvinas/  US04335A1051  /

IEX
2024-05-01  9:59:56 PM Chg. +0.64 Volume Bid- Ask- High Low
32.47USD +2.01% 21,238
Turnover: 682,083.48		 -Bid Size: - -Ask Size: - 33.05 31.34
GlobeNewswire 04-24 Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
GlobeNewswire 04-11 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
GlobeNewswire 03-18 Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire 03-04 Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire 02-27 Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 02-20 Arvinas Announces Chief Financial Officer Transition
GlobeNewswire 02-20 Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for ...
GlobeNewswire 02-15 Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
GlobeNewswire 02-14 Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focu...
GlobeNewswire 02-14 Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in C...
GlobeNewswire 02-06 Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment o...
GlobeNewswire 02-01 Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
GlobeNewswire 01-16 Arvinas Appoints Jared Freedberg as General Counsel
GlobeNewswire 2023-12-15 Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Com...
GlobeNewswire 2023-12-06 Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 202...
GlobeNewswire 2023-12-05 Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Pa...
GlobeNewswire 2023-11-28 Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Ant...
GlobeNewswire 2023-11-27 Arvinas Announces Oversubscribed $350 Million Private Placement
GlobeNewswire 2023-11-13 Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
GlobeNewswire 2023-11-07 Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 2023-11-02 Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire 2023-10-22 Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and U...
GlobeNewswire 2023-10-18 Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
GlobeNewswire 2023-10-15 Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
GlobeNewswire 2023-10-15 Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 20...